SCHEMBL30855317

SCHEMBL30855317

Clc1cccc(N2CCN(CCC3CCNCC3)CC2)c1Cl

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 15/20 0.73
▸ DRD3 P35462 14/20 0.62
▸ HTR1A P08908 2/20 0.59
▸ ADRA2A P08913 2/20 0.59
▸ DRD4 P21917 2/20 0.59
▸ HTR2A P28223 2/20 0.59
▸ HTR2C P28335 2/20 0.59
▸ HTR7 P34969 2/20 0.59
▸ ADRA1A P35348 2/20 0.59
▸ HRH1 P35367 2/20 0.59
▸ ABCB11 O95342 1/20 0.59
▸ CHRM2 P08172 1/20 0.59
▸ CHRM1 P11229 1/20 0.59
▸ DRD1 P21728 1/20 0.59
▸ DRD5 P21918 1/20 0.59
▸ HTR2B P41595 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ ADRB1 P08588 2/20 0.58
▸ CHRM4 P08173 1/20 0.58
▸ CHRM5 P08912 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843723 1.00 DRD2 (0.73) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL30855285 0.93 DRD2 (0.64) DRD2DRD3HTR1ADRD4HTR2A
SCHEMBL22303331 0.88 DRD2 (0.79) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL22302295 0.87 DRD2 (0.69) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL18073600 0.87 DRD2 (0.77) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL28475732 0.86 DRD2 (0.75) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL24573863 0.85 DRD2 (0.77) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL22302843 0.85 DRD2 (0.77) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL1310960 0.85 DRD2 (1.00) DRD2DRD3HTR1AADRA2ADRD4
SCHEMBL2034152 0.85 DRD2 (1.00) DRD2DRD3HTR1AADRA2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594294-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2025-08-06 — — EP disclosed
WO-2024072930-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-04-04 — — WO disclosed
Send feedback